Using Indocyanine Green Extraction to Predict Liver Function After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

被引:21
|
作者
Suresh, Krithika [1 ]
Owen, Dawn [1 ,2 ]
Bazzi, Latifa [2 ]
Jackson, William [2 ]
Ten Haken, Randall K. [2 ]
Cuneo, Kyle [2 ]
Feng, Mary [2 ,3 ]
Lawrence, Theodore S. [2 ]
Schipper, Matthew J. [1 ,2 ]
机构
[1] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[3] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
基金
美国国家卫生研究院;
关键词
CHILD-PUGH; RADIOTHERAPY; SORAFENIB; CLEARANCE; TOXICITY; OUTCOMES; IMPACT; SCORE;
D O I
10.1016/j.ijrobp.2017.09.032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To test the hypothesis that mid-treatment measures of the retention of indocyanine green after 15 minutes (ICGR15) would improve the prediction of posttreatment liver function in the setting of hepatocellular carcinoma. Methods and Materials: Between 2006 and 2015, 144 patients with hepatocellular carcinoma received 175 courses of stereotactic body radiation therapy (SBRT). Patient data, such as age, sex, portal vein thrombosis, cirrhosis, Child-Pugh (CP) score, prior liver-directed therapies, and liver function tests, including albumin-bilirubin (ALBI) and ICG clearance, and dosimetric data, such as tumor volume and radiation dose, were collected. Toxicity was evaluated as a 2-point increase in CP score or a change in ALBI score at 3 months from start of SBRT. Logistic or linear regression was used to build toxicity prediction models based on patient and tumor characteristics and ICG clearance variables. Performance of the models for the binary CP outcome was summarized using area under the curve and receive operating characteristic curves. Likelihood ratio tests were used to evaluate whether the model fit improved after incorporating the ICG variable information. Results: In multivariable analysis age, baseline ICGR15, and change in ICGR15 were associated with toxicity defined by increased CP score. For the continuous ALBI outcome, being female, having cirrhosis, and increasing radiation dose were associated with increased toxicity. When incorporating ICGR15 into these models, an increase in ICGR15 from baseline to mid-treatment was most consistently significantly associated with an increase in toxicity. Conclusions: Incorporation of ICGR15 variables significantly improves the prediction of post-SBRT liver function. The use of ICGR15 can facilitate the delivery of the maximum safe dose of radiation for patients with hepatocellular carcinoma and has the potential to improve uncomplicated tumor control and survival. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 50 条
  • [21] Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization
    Hardy-Abeloos, Camille
    Lazarev, Stanislav
    Ru, Meng
    Kim, Edward
    Fischman, Aaron
    Moshier, Erin
    Rosenzweig, Kenneth
    Buckstein, Michael
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (05): : 968 - 976
  • [22] Role of stereotactic body radiation therapy for hepatocellular carcinoma
    Naoko Sanuki
    Atsuya Takeda
    Etsuo Kunieda
    World Journal of Gastroenterology, 2014, (12) : 3100 - 3111
  • [23] Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
    Eriguchi, Takahisa
    Tsukamoto, Nobuhiro
    Kuroiwa, Nobuko
    Nemoto, Takafumi
    Ogata, Takeru
    Okubo, Yusuke
    Nakano, Shigeru
    Sugawara, Akitomo
    PRACTICAL RADIATION ONCOLOGY, 2021, 11 (01) : 44 - 52
  • [24] Stereotactic body radiation therapy for the management of hepatocellular carcinoma
    Roquette, I.
    Bogart, E.
    Lacornerie, T.
    Ningarhari, M.
    Le Deley, M.
    Lartigau, E.
    Mirabel, X.
    Pasquier, D.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S381 - S381
  • [25] Role of stereotactic body radiation therapy for hepatocellular carcinoma
    Sanuki, Naoko
    Takeda, Atsuya
    Kunieda, Etsuo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (12) : 3100 - 3111
  • [26] Stereotactic Body Radiation Therapy in Recurrent Hepatocellular Carcinoma
    Huang, Wen-Yen
    Jen, Yee-Min
    Lee, Meei-Shyuan
    Chang, Li-Ping
    Chen, Chang-Ming
    Ko, Kai-Hsiung
    Lin, Kuen-Tze
    Lin, Jang-Chun
    Chao, Hsing-Lung
    Lin, Chun-Shu
    Su, Yu-Fu
    Fan, Chao-Yueh
    Chang, Yao-Wen
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (02): : 355 - 361
  • [27] Role of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma
    Abualnil, Aseel Y.
    Kumar, Ritesh
    George, Mridula A.
    Lalos, Alexander
    Shah, Mihir M.
    Deek, Matthew P.
    Jabbour, Salma K.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 33 (01) : 173 - 195
  • [28] Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
    Jang, W. I.
    Kim, M. S.
    Yoo, H. J.
    Paik, E. K.
    Cha, Y.
    Han, C. J.
    Park, S. C.
    Kim, S. B.
    Cho, E. H.
    Kang, J. K.
    Seo, Y. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E141 - E141
  • [29] Stereotactic body radiation therapy in recurrent hepatocellular carcinoma
    Huang, Wen-Yen
    Jen, Yee-Min
    Lee, Meei-Shyuan
    Chang, Li-Ping
    Chen, Chang-Ming
    Ko, Kai-Hsiung
    Lin, Kuen-Tze
    Lin, Jang-Chun
    Chao, Hsing-Lung
    Lin, Chun-Shu
    Su, Yu-Fu
    Fan, Chao-Yueh
    Chang, Yao-Wen
    International Journal of Radiation Oncology Biology Physics, 2012, 84 (02): : 355 - 361
  • [30] Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
    Murray, Louise J.
    Dawson, Laura A.
    SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (03) : 247 - 255